IPROTEOS SL
A Healthtech startup included in the Barcelona & Catalonia Startup Hub

IPROTEOS
EXIT
Iproteos seeks to improve human health by creating therapeutics for diseases that are currently difficult to target. Our IPROTech platform quickly and efficiently delivers cell-permeable and bio-available drug candidates to modulate "undruggable" targets. The effectiveness of IPROTech has been proved by Iproteos' pipeline and in multiple ongoing strategic partnerships.
Industries & Technologies
Financial data
Other information
Funding
(May 2020)
acquisition
Investors: Accure Therapeutics
1.5M € (July 2016)
Minority stake unknown %
Investors: CAIXA CAPITAL RISC, KINLED HOLDING LTD, ASCIL PROYECTOS SL, EMPRESA NACIONAL DE INNOVACION SA
0.3M € (June 2016)
Minority stake unknown %
Investors: CAPITAL CELL
0.1M € (October 2014)
Minority stake
Investors: UNDISCLOSED PRIVATE INVESTORS
Source: Press releases newsletters & platforms company websites annual reports & accounts regulatory body sites & stock exchanges
@iproteos
Other startups near startup IPROTEOS
similar companies
Collaborators of Barcelona & Catalonia Startup Hub.
We teamed up with business associations, universities and startup incubators to create the Barcelona & Catalonia Startup Hub.